<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>Ipamorelin Research</title>
  <subtitle>Ipamorelin research hub — the most selective growth hormone secretagogue, ghrelin receptor agonist mechanisms, cortisol-sparing profile, bone density, GI motility, and combination research.</subtitle>
  <link href="https://ipamorelin-research.com/feed.xml" rel="self" type="application/atom+xml"/>
  <link href="https://ipamorelin-research.com/" rel="alternate" type="text/html"/>
  <link href="https://pubsubhubbub.appspot.com/" rel="hub"/>
  <id>https://ipamorelin-research.com/</id>
  <updated>2026-04-16T00:00:00Z</updated>
  <author>
    <name>Ipamorelin Research</name>
    <uri>https://ipamorelin-research.com</uri>
  </author>
  <generator>Eleventy</generator>
  <rights>Copyright 2026 Ipamorelin Research</rights>
  <entry>
    <title>Ipamorelin: The Selective Growth Hormone Secretagogue</title>
    <link href="https://ipamorelin-research.com/articles/ipamorelin-selective-growth-hormone-secretagogue/"/>
    <id>https://ipamorelin-research.com/articles/ipamorelin-selective-growth-hormone-secretagogue/</id>
    <updated>2026-04-09T00:00:00Z</updated>
    <published>2026-01-15T00:00:00Z</published>
    <summary>Research review of Ipamorelin — the highly selective GHS-R agonist studied for growth hormone release without significant effects on cortisol, prolactin, or appetite.</summary>
    <author>
      <name>Ipamorelin Research</name>
    </author>
    <category term="Peptide Deep Dive"/>
  </entry>
  <entry>
    <title>CJC-1295 + Ipamorelin: The Combination Research Protocol</title>
    <link href="https://ipamorelin-research.com/articles/cjc-1295-ipamorelin-combination-research-protocol/"/>
    <id>https://ipamorelin-research.com/articles/cjc-1295-ipamorelin-combination-research-protocol/</id>
    <updated>2026-04-09T00:00:00Z</updated>
    <published>2026-01-15T00:00:00Z</published>
    <summary>Why CJC-1295 and Ipamorelin are combined in research — complementary receptor targets, synergistic GH release, and study design considerations.</summary>
    <author>
      <name>Ipamorelin Research</name>
    </author>
    <category term="Peptide Deep Dive"/>
  </entry>
  <entry>
    <title>Growth Hormone Secretagogues: A Complete Research Guide</title>
    <link href="https://ipamorelin-research.com/articles/growth-hormone-secretagogues-complete-research-guide/"/>
    <id>https://ipamorelin-research.com/articles/growth-hormone-secretagogues-complete-research-guide/</id>
    <updated>2026-04-09T00:00:00Z</updated>
    <published>2026-01-15T00:00:00Z</published>
    <summary>Everything researchers need to know about GH secretagogues — Ipamorelin, CJC-1295, GHRP-6, Tesamorelin, and how they differ in mechanism and selectivity.</summary>
    <author>
      <name>Ipamorelin Research</name>
    </author>
    <category term="Category Roundup"/>
  </entry>
  <entry>
    <title>What Is Tesamorelin? GHRH Analog Research Review</title>
    <link href="https://ipamorelin-research.com/articles/what-is-tesamorelin-ghrh-analog-research/"/>
    <id>https://ipamorelin-research.com/articles/what-is-tesamorelin-ghrh-analog-research/</id>
    <updated>2026-04-09T00:00:00Z</updated>
    <published>2026-01-15T00:00:00Z</published>
    <summary>Research review of Tesamorelin — the synthetic GHRH analog studied for growth hormone secretion and visceral adipose tissue reduction.</summary>
    <author>
      <name>Ipamorelin Research</name>
    </author>
    <category term="Peptide Deep Dive"/>
  </entry>
  
</feed>
